Iindaba ezimnandi:

I-Bioantibody igqibe umjikelo wayo wokuqala wenkxaso-mali ephantse ibe li-100 lezigidi zeeyuan.Le nkxaso-mali ikhokelwa ngokudibeneyo yiFang Fund, i-New Industry Investment, i-Guoqian Venture Investment, i-bondshine capital kunye ne-Phoeixe Tree Investment.
Iimali ziya kusetyenziselwa ukukhawulezisa ukucwangciswa okunzulu kwe-Bioantibody ekungeniseni iiplatifomu ezizenzekelayo kunye nezihlanganisiweyo kunye ne-customization ye-OEM/ODM iqonga lee-antibodies, #IVD Products, kunye nenkonzo yobugcisa ehambelanayo njl.

I-Bioantibody igxile kwi-R&D, imveliso kunye nokuthengiswa kwezinto ezisisiseko ze-IVD kunye ne-biopharmaceuticals.Ngokusekwe kubuchule obuphezulu obujoliswe kwitekhnoloji ye-hybridoma cell fusion kunye nezinto ezixhasayo zokukhula kweeseli kunye neqonga lokuhlola eliphezulu, inkampani iphuhlise inani leemveliso ezinomgangatho wokusebenza othelekiswa okanye odlulayo wemathiriyeli ekrwada ye-IVD yokuqala yehlabathi. , kwaye yaqonda ngempumelelo urhwebo.Iyaziwa kakhulu kwaye ithengwa ngokuphindaphindiweyo ngabathengi beenkampani ezininzi ezaziwayo ezidweliswe kwi-IVD e-China.

I-Bioantibody kususela ekusekweni kwayo yahlala inyanisekile kwiminqweno yayo yantlandlolo, iqhubela phambili nokuvelisa izinto ezintsha kunye neenkonzo zokhathalelo lwezempilo oluxhotyiswe ngetekhnoloji.

Sivuyisana nawe!!